Source-grounded facts extracted from ALLURION TECHNOLOGIES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
R. Jason Richey resigned as Class II Director and Audit Committee Chair at ALLURION TECHNOLOGIES, INC..
“On June 24, 2026, R. Jason Richey, a Class II member of the board of directors (the “Board”) of Allurion Technologies, Inc. (the “Company”), notified the Company of his resignation from the Board and his role as the chairperson of the Audit Committee of the Board (the “Audit Committee”), effective the same day.”
ALLURION TECHNOLOGIES, INC.: Amended certificate of incorporation to effect a 1-for-15 reverse stock split (effective 2026-06-18).
“Following the Annual Meeting, the Pricing Committee of the Board approved a reverse stock split of the Common Stock at a ratio of 1-for-15 (the “Reverse Stock Split”) and on June 12, 2026, the Company filed an amendment, as amended by a Certificate of Correction thereto (the “Certificate of Amendment”), to its Certificate of Incorporation to effectuate the Reverse Stock Split.”
ALLURION TECHNOLOGIES, INC. engaged CBIZ CPAs P.C. as its auditor.
“On May 20, 2026, the Audit Committee appointed CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, effective as of May 20, 2026.”
ALLURION TECHNOLOGIES, INC. dismissed Deloitte & Touche LLP as its auditor.
“On May 22, 2026 (the “Effective Date”), Deloitte was dismissed as our independent registered public accounting firm.”
ALLURION TECHNOLOGIES, INC. received a nyse delisting notice notice regarding market value (rules 802.01B).
“March 6, 2026, the New York Stock Exchange (“NYSE”) notified Allurion Technologies, Inc. (“Allurion” or the “Company”) that it has determined to commence proceedings to delist the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase 0.056818 shares of Common Stock, with an exercise price of $202.50 per share of Common Stock (the “Warrants”), as a result of the Company’s non-compliance with Rule 802.01B of the NYSE Listed Company Manual that requires listing companies to maintain an average global market capitalization of at least $15 million over a”
ALLURION TECHNOLOGIES, INC. received a nyse delisting notice notice regarding other (rules 802.01B).
“March 2, 2026, Allurion Technologies, Inc., a Delaware corporation (the “Company”) announced that it received a letter (the “Delisting Notice”) from the staff of the New York Stock Exchange (the “Exchange” or “NYSE”) indicating that the Company does not meet certain of the Exchange’s continued listing standards as set forth in Section 802.01B of the NYSE Listed Company Manual that require listed companies to maintain either (i) at least $50 million in stockholders’ equity or (ii) at least $50 million in total market capitalization on a 30-trading day average basis and that the Exchange will be”
ALLURION TECHNOLOGIES, INC. issued 2,659,565 shares of Common Stock of warrant to certain holders of existing warrants for aggregate gross proceeds of approximately $3.0 million from cash exercise of Existing Warrants.
“new warrants (the “New Warrants”) to purchase up to an aggregate of 5,319,130 shares of Common Stock. The Company expects to receive aggregate gross proceeds of approximately $3.0 million from the exercise of the Existing Warrants by the Exercising Holders. Each New Warrant is exercisable into shares of Common Stock at a price per share of $1.15, will initially be”
ALLURION TECHNOLOGIES, INC. entered into Inducement Letter with certain holders (Exercising Holders) valued at approximately $3.0 million (effective 2026-02-24).
“On February 24, 2026, Allurion Technologies, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with certain holders (the “Exercising Holders”)”
ALLURION TECHNOLOGIES, INC. issued preferred stock to entities managed by RTW Investments, LP.
“the Company entered into a securities purchase and exchange agreement (the “Exchange Agreement”) with certain entities managed by RTW Investments, LP (collectively, “RTW”), pursuant to which RTW has agreed to exchange all of the (i) principal amount of convertible senior secured notes”
ALLURION TECHNOLOGIES, INC. issued up to 2,994,012 shares of Common Stock of warrant to certain accredited investors.
“the Company agreed to issue and sell 2,994,012 shares (the “Private Placement Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and accompanying common warrants to purchase up to 2,994,012 shares of Common Stock (the “Private Placement Warrants,” and together with the Private Placement Shares, the “Private Placement Securities”)”
ALLURION TECHNOLOGIES, INC. issued 2,994,012 shares of common stock to certain accredited investors for aggregate purchase price of approximately $5 million at a purchase price of $1.67 per Private Placement Share and accompanying Private Placement Warrant.
“the Company agreed to issue and sell 2,994,012 shares (the “Private Placement Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and accompanying common warrants to purchase up to 2,994,012 shares of Common Stock (the “Private Placement Warrants,” and together with the Private Placement Shares, the “Private Placement Securities”), for an aggregate purchase price of approximately $5 million at a purchase price of $1.67 per Private Placement Share and accompanying Private Placement Warrant”
ALLURION TECHNOLOGIES, INC. reported that prior financial statements should not be relied upon.
“(the “Company”) concluded that certain of the Company’s previously issued financial statements, as described below, should no longer be relied upon due to errors identified in the accounting related to the fair value of the RIFA and the Notes (each as defined below), for which the impacts are non-cash. The Company does not expect, however, that the correction of such amounts will have any impact on reported revenue, gross margin, operating expenses, or cash. In February 2023, the Company entered into the revenue interest financing agreement, dated as of February 9, 2023 (the “RIFA”). In addition, in April 2024, the Company issued and sold $48.0 million of convertible senior secured notes (the “Notes”). The Company had elected to account for the RIFA and the Notes using the fair value option as permitted under ASC 825, Financial Instruments . While preparing the condensed consolidated fin”
ALLURION TECHNOLOGIES, INC. announced a restructuring with charges of approximately $1.5 million (approximately 70 employees, or approximately 65% of its workforce).
“employees between August 4, 2025 and August 6, 2025. As part of this Restructuring Plan, the Company expects to incur severance and severance-related charges of approximately $1.5 million. The Company’s estimated restructuring charges is based on a number of assumptions. Actual results may differ materially and the Company may also incur other charges or cash”
R. Jason Richey was appointed as Class II Director at ALLURION TECHNOLOGIES, INC..
“appointed R. Jason Richey to the Board as a Class II director”
ALLURION TECHNOLOGIES, INC.: Approved and filed a charter amendment to effect a 1-for-25 reverse stock split, effective January 3, 2025 (effective 2025-01-03).
“Effective as of 12:01 a.m. Eastern Time on January 3, 2025, the Company filed an amendment (the "Certificate of Amendment") to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate the Reverse Stock Split.”
Shantanu Gaur changed role as principal financial officer and principal accounting officer at ALLURION TECHNOLOGIES, INC..
“Shantanu Gaur, Chief Executive Officer of the Company, will serve as the Company’s principal financial officer and principal accounting officer, effective as of the close of business on November 13, 2024, until a replacement for Mr. Geberth is found.”
Christopher Geberth resigned as Chief Financial Officer at ALLURION TECHNOLOGIES, INC..
“Christopher Geberth, Chief Financial Officer of Allurion Technologies, Inc. (the “Company”), notified the Company of his decision to resign, effective as of the close of business on November 13, 2024, to pursue other interests.”
Keith Johns was appointed as Class III director at ALLURION TECHNOLOGIES, INC..
“On September 2, 2024, the Board of Directors (the "Board") of Allurion Technologies, Inc. ("Allurion" or the "Company") appointed Keith Johns to the Board as a Class III director to fill a vacancy created by an increase in the size of the Board from seven members to eight members, effective September 2, 2024.”
ALLURION TECHNOLOGIES, INC. reported first quarter ended March 31, 2024 results: revenue $9.4 million. Guidance reaffirmed.
“Total revenue for the quarter ended March 31, 2024 was $9.4 million compared to $14.1 million for the same period in 2023”
ALLURION TECHNOLOGIES, INC. reported first quarter 2024 results: revenue $9.2 million to $9.3 million.
“Management expects preliminary unaudited results for the period as follows: • Revenue in the range of $9.2 million to $9.3 million, reflecting growth of between 12%-13% over the fourth quarter of 2023”
ALLURION TECHNOLOGIES, INC. terminated Fortress Credit Agreement.
“The Company has terminated and repaid in full the outstanding borrowings and other obligations under the Fortress Credit Agreement.”
ALLURION TECHNOLOGIES, INC. amended First Amendment to the Original Note Purchase Agreement with RTW Investments, LP, as agent for the purchasers, and Acquiom Agency Services LLC (effective 2024-04-16).
“Subsequently, on April 16, 2024, the Company, the Principal Purchaser, the Purchasers and Acquiom entered into the First Amendment to the Original Note Purchase Agreement (the “Amendment”; the Original Note Purchase Agreement, as amended by the Amendment, the “Amended Note Purchase Agreement”).”
ALLURION TECHNOLOGIES, INC. entered into Original Note Purchase Agreement with RTW Investments, LP, as agent for the purchasers, and Acquiom Agency Services LLC valued at $48 million (effective 2024-04-14).
“On April 14, 2024, Allurion Technologies, Inc., a Delaware corporation (the “Company”), RTW Investments, LP (“RTW”), as agent for the purchasers (the “Purchasers”) party thereto from time to time (RTW in such capacity, the “Principal Purchaser”), and Acquiom Agency Services LLC (“Acquiom”), as collateral agent for the Purchasers and the Principal Purchaser, entered into a Note Purchase Agreement (the “Original Note Purchase Agreement”).”
Milena Alberti-Perez was appointed as Director at ALLURION TECHNOLOGIES, INC..
“appointed Milena Alberti-Perez to the Board as a Class III director to fill the vacancy on the Board, effective immediately.”
ALLURION TECHNOLOGIES, INC. reported fiscal year 2024 results: revenue $60 - $65 million. Guidance initiated.
“24 Outlook • Anticipated procedural volume growth of approximately 20%, despite a reduction in overall marketing spend, reflecting increased penetration in key direct markets and reallocation of marketing spend to more efficient channels • Revenue guidance of $60 - $65 million , reflecting growth of approximately 13% - 23% year over year • Expected gross margins of 77-79%, reflecting durable pricing of our gastric balloon as well as initial commercialization efforts of the digital platform • Targeted cash burn reduced to approximately $7 - $8 million per quarter Key 2024 Growth Catalysts • Accelerated procedure volume growth across direct markets where Allurion has fully established direct sales and support models • Release of new clinical data, including the AUDACITY FDA pivotal trial read-out expected by end of year, and additional data validating Allurion’s best-in-class weight loss a”
ALLURION TECHNOLOGIES, INC. reported the fiscal year ended December 31, 2023 results: revenue $53 - $54 million.
“2023 full year revenue is expected to be in the range of $53 - $54 million”
ALLURION TECHNOLOGIES, INC. reported the quarter ended December 31, 2023 results: revenue $8.1 - $8.3 million.
“Fourth quarter revenue is expected to be in the range of $8.1 - $8.3 million”
ALLURION TECHNOLOGIES, INC. amended Amendment No. 1 to Credit Agreement and Guaranty with Fortress Credit Corp., as administrative agent, and the lenders party thereto (effective 2023-12-29).
“On December 29, 2023 (the “Amendment Effective Date”), Allurion Technologies, Inc. (the “Company”) and its wholly-owned subsidiaries Allurion Technologies, LLC (the “Borrower”) and Allurion Australia Pty Ltd, entered into Amendment No. 1 (the “Amendment”) to the Credit Agreement and Guaranty, dated as of August 1, 2023 (the “Existing Credit Agreement”; as amended by the Amendment, the “Credit Agreement”), by and among the Company, the Borrower, the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto (the “Lenders” and each, a “Lender”) and Fortress Credit Corp., as administrative agent for the Lenders (“Fortress”).”
ALLURION TECHNOLOGIES, INC. entered into Registration Rights Agreement with Chardan Capital Markets LLC (effective 2023-12-18).
“On December 18, 2023, Allurion Technologies, Inc., a Delaware corporation (the “Company”) entered into a ChEF Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”), each with Chardan Capital Markets LLC (“Chardan”) related to a “ChEF,” Chardan’s committed equity facility (the “Facility”).”
ALLURION TECHNOLOGIES, INC. entered into ChEF Purchase Agreement with Chardan Capital Markets LLC valued at $100,000,000 in aggregate gross purchase price (effective 2023-12-18).
“On December 18, 2023, Allurion Technologies, Inc., a Delaware corporation (the “Company”) entered into a ChEF Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”), each with Chardan Capital Markets LLC (“Chardan”) related to a “ChEF,” Chardan’s committed equity facility (the “Facility”).”
Benoit Chardon resigned as Chief Commercial Officer at ALLURION TECHNOLOGIES, INC..
“On December 12, 2023, the Company's Chief Commercial Officer, Benoit Chardon, resigned effective December 31, 2023.”
ALLURION TECHNOLOGIES, INC. reported the quarter ended September 30, 2023 results: revenue $18.2 million.
“Total revenue for the quarter ended September 30, 2023 was $18.2 million compared to $16.1 million for the same period in 2022, and $13.0 million for the second quarter of 2023.”
ALLURION TECHNOLOGIES, INC.: Compute Health ceased to be a shell company upon closing of the Business Combination.
“Compute Health ceased to be a shell company upon the closing of the Business Combination and, additionally, ceased to exist as it merged into New Allurion.”
ALLURION TECHNOLOGIES, INC.: Adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors.
“the Company’s board of directors approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of New Allurion.”
ALLURION TECHNOLOGIES, INC.: Amended and restated bylaws in connection with the Business Combination.
“and amended and restated its bylaws (as amended, the “ Bylaws ”).”
ALLURION TECHNOLOGIES, INC.: Amended and restated certificate of incorporation in connection with the Business Combination.
“In connection with the consummation of the Business Combination, New Allurion amended and restated its certificate of incorporation (as amended, the “ Charter ”)”
ALLURION TECHNOLOGIES, INC. underwent a change of control involving Compute Health Acquisition Corp. for Each share of Compute Health Class A Common Stock converted into right to receive 1.420455 shares of New Allurion Common Stock; each Compute Health Public Warra (closed 2023-08-01).
“tion (the “ Company ”, “ New Allurion ”, “ we ” and “ our ”), entered into that certain business combination agreement (as the same was amended as of May 2, 2023, the “ Business Combination Agreement ”), dated as of February 9, 2023, by and among the Company, Compute Health Acquisition Corp. (“ Compute Health ”), Compute Health Corp., a Delaware corporation and a then-direct, wholly-owned subsidiary of Compute Health (“ Merger Sub I ”), Compute Health LLC, a Delaware limited liability company and a then-direct, wholly-owned subsidiary of Compute Health (“ Merger Sub II ” and, together with Merger Sub I, the “ Merger Subs ”), and Allurion Technologies Opco, Inc.”
ALLURION TECHNOLOGIES, INC. incurred convertible notes of $2,000,000 with RTW Investments, LP at unknown maturing unknown.
“Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing (a) each Backstop Purchaser purchased $2 million of the aggregate principal amount outstanding under HVL’s Allurion Convertible Note, (b) New Allurion canceled the existing Allurion Convertible Note held by HVL and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c) New Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of the Closing Date and an original principal amount of $2 million each”
ALLURION TECHNOLOGIES, INC. incurred convertible notes of $2,000,000 with CFIP2 ALLE LLC at unknown maturing unknown.
“Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing (a) each Backstop Purchaser purchased $2 million of the aggregate principal amount outstanding under HVL’s Allurion Convertible Note, (b) New Allurion canceled the existing Allurion Convertible Note held by HVL and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c) New Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of the Closing Date and an original principal amount of $2 million each”
ALLURION TECHNOLOGIES, INC. entered into Fortress Credit Agreement with Fortress Credit Corp. as administrative agent and lenders from time to time valued at $60.0 million senior secured term loan, interest at 6.44% plus the greater of prime rate and 3.0%, m.
“At the Intermediate Merger Effective Time, a term loan facility (the “ Term Loan Facility ”) pursuant to a credit agreement and guaranty (the “ Credit Agreement ”), was entered into by and among Allurion Technologies, LLC, a Delaware limited liability company (the surviving company in the Final Merger) (the “ Borrower ”), New Allurion, Allurion Australia Pty Ltd, certain subsidiaries of New Allurion that may be required to provide guaranties from time to time thereunder, each lender from time to time party thereto (each, a “ Lender ” and collectively, the “ Lenders ”), and Fortress Credit Corp., as administrative agent for the Lenders (“ Fortress ”).”
ALLURION TECHNOLOGIES, INC. entered into Investor Rights and Lock-Up Agreement with Sponsor and certain former equity holders of Allurion valued at Registration rights and lock-up restrictions for shares of New Allurion Common Stock.
“Pursuant to the Business Combination Agreement, in connection with the Closings, an investor rights agreement and lock-up agreement (the “ Investor Rights Agreement ”) was entered into by and among New Allurion, the Sponsor, certain former equity holders of Allurion and certain other parties (each, an “ Investor ”) immediately prior to the Intermediate Merger Effective Time, pursuant to which New Allurion agreed to, within 30 days of the Intermediate Merger Effective Time, register for resale, pursuant to Rule 415 under the Securities Act of 1933, as amended (the “ Securities Act ”), certain shares of New Allurion Common Stock and other equity securities of New Allurion that are held by the parties thereto from time to time.”
Christopher Geberth was appointed as Chief Financial Officer at ALLURION TECHNOLOGIES, INC..
“Effective upon the closing of the Business Combination, Allurion entered into a new employment agreement with Mr. Geberth, pursuant to which Allurion will continue to employ Mr. Geberth as Chief Financial Officer on an “at will” basis.”
Shantanu Gaur was appointed as Chief Executive Officer at ALLURION TECHNOLOGIES, INC..
“Effective upon the closing of the Business Combination, Allurion entered into a new employment agreement with Dr. Gaur, pursuant to which Allurion will continue to employ Dr. Gaur as Chief Executive Officer on an “at will” basis.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.